title: Treatment with DAV for advanced-stage hemangiosarcoma in dogs.
abstract: Hemangiosarcoma (HSA) is an aggressive disease that is fairly common in the dog. The authors evaluated a doxorubicin, dacarbazine, and vincristine (DAV) combination protocol in dogs with nonresectable stage II and stage III HSA. Twenty-four dogs were enrolled in this prospective, phase 2 study. Doxorubicin and dacarbazine were administered on day 1 while vincristine was administered on days 8 and 15. The protocol was repeated every 21 days for a maximum of six cycles or until disease progression. Toxicity and efficacy were assessed by clinical and laboratory evaluation and by questionnaires completed by the owners. Of the 24 included dogs, 19 were evaluable for response. The response rate (including five complete responses and four partial responses) was 47.4%. Median time to tumor progression was 101 days and median overall survival was 125 days. Significant toxicities were noted, including 41 high-grade hematologic and 12 high-grade gastrointestinal toxic events. Five dogs discontinued treatment due to chemotherapy-related toxicities, but no treatment-related deaths occurred. Multivariate analysis identified patient age (relative risk [RR], 2.3, P=0.049) to be negatively associated with time to progression whereas dacarbazine dose reductions (RR, 0.06, P=0.031) were positively associated with time to progression. Dacarbazine dose reduction was the sole factor positively associated with overall survival (RR, 0.28, P=0.015). In conclusion, the DAV combination appears to offer clinical responses and may prolong survival in dogs with advanced-stage HSA.
authors.affiliation: Center for Comparative Oncology, Michigan State University, East Lansing, MI, USA. dervisis@cvm.msu.edu
authors.forename: Nikolaos G
authors.initials: NG
authors.lastname: Dervisis
authors.forename: Pedro A
authors.initials: PA
authors.lastname: Dominguez
authors.forename: Rebecca G
authors.initials: RG
authors.lastname: Newman
authors.forename: Casey D
authors.initials: CD
authors.lastname: Cadile
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Kitchell
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant / Q000662:veterinary; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging / Q000662:veterinary; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin